SAI Parenterals

Hyderabad, India Founded: 2001 • Age: 25 yrs Listed
Parenteral products including sterile injections and pharmaceutical services are provided.
Request Access
Report Incorrect Data
Page last updated

About SAI Parenterals

SAI Parenterals is a publicly listed company based in Hyderabad (India) founded in 2001. Parenteral products including sterile injections and pharmaceutical services are provided. It operates on a Managed Services and Direct-to-Consumer (D2C) model. SAI Parenterals has raised $5.83 million across 1 funding round from investors including Blue Lotus Capital, Samarsh Capital and Vyom Partners. The company has 257 employees. Its Indian entity Sai Parenteral's Limited reported revenue of ₹390 Cr. SAI Parenterals offers products and services including Injectables, Branded Generic Formulations, and CDMO Services. Its focus areas include Pharmaceuticals and Generic Drugs.

Company details

Sai Parenterals Limited is engaged in the research, development, and manufacturing of pharmaceutical formulations. Operations are structured across branded generic formulations and contract development manufacturing organization (CDMO) services. The portfolio covers multiple therapeutic areas such as cardiovascular, neuropsychiatry, and respiratory health. Products are manufactured in various dosage forms including injectables, tablets, and capsules. Facilities are located in Hyderabad, Telangana, with a focus on sterile injectables for critical care. Global presence is established in regulated and semi-regulated markets across Australia, Southeast Asia, and the Middle East.

  • Headquarters Hyderabad, India
  • Employees 257
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website saiparenterals.com
  • Legal Name Sai Parenterals Limited
Operational Areas
Healthcare → Traditional Health & Nutrition
Key Metrics
  • Market Cap
    ₹2,134 Cr

    SAIPARENT · NSE

  • Share Price
    ₹466.35

    -3.44% today

  • Revenue
    ₹381 Cr

    FY 2025-26 · +133.6% YoY

  • EBITDA
    ₹38.77 Cr

    Margin 10.2%

  • Net Profit
    ₹14.27 Cr

    FY 2025-26 · -1.0% YoY

  • P/E (TTM)
    82.7x

    P/B 10.0x

  • ROE
    4.9%

    ROCE 4.8%

  • Debt / Equity
    0.96

    Interest cover 84.4x

  • Total Equity Funding
    $5.83M (USD)

    in 1 rounds

  • Latest Funding Round
    $5.83M (USD), Series A

    Jul 2025

  • Investors
    Blue Lotus Capital

    & 2 more

  • Employee Count
    257

Products & Services of SAI Parenterals

SAI Parenterals offers a comprehensive portfolio of products and services, including Injectables, Branded Generic Formulations, and CDMO Services.

Injectables
Pharmaceuticals

Sterile injectables are manufactured for critical care therapies.

Branded Generic Formulations
Pharmaceuticals

Generic formulations are produced for diverse therapeutic areas.

CDMO Services
Pharmaceutical Services

End-to-end solutions are provided for pharmaceutical manufacturing.

Funding Insights of SAI Parenterals

SAI Parenterals has successfully raised a total of $5.83M through 1 strategic funding round. The most recent funding activity was a Series A round of $5.83 million completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $5.83M
  • Total Rounds 1
  • Last Round Series A — $5.83M
  • First Round $5.83M

    (Jul 2025)

  • Investors Count 3

All 1 funding rounds of SAI Parenterals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jul 2025$5.83MSeries A–Samarsh Capital, Blue Lotus Capital
Vyom Partners
Valuation history

3 investors in total: 3 institutional.

Investors in SAI Parenterals

SAI Parenterals has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Blue Lotus Capital, Samarsh Capital and Vyom Partners.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Samarsh Capital
Investment and capital management services are provided by Samarsh Capital.
2024samarshcapital.comBengaluru, India
Blue Lotus Capital
Independent firm managing funds and investing in small and midcap companies worldwide.
2015bluelotuscap.comMumbai, India
Vyom Partners
Premium access

Investor details for SAI Parenterals

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Sai Parenteral's Limited (SAI Parenterals)

Sai Parenteral's Limited is the primary company behind SAI Parenterals. The board of Sai Parenteral's Limited currently have 6 directors; the longest-serving is Aruna Karusala, appointed in 2016. 9 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Aruna Karusala
DIN 01673731
Director16 Aug 201610 yrs 2 moSai Parenteral's Limited
Vijitha Gorrepati
DIN 03492979
Whole-time director16 Aug 201610 yrs 2 moSai Parenteral's Limited
Anil Kumar Karusala
DIN 01866646
Managing Director19 Nov 20214 yrs 11 moSai Parenteral's Limited
Bhagyashri Dharmasa Zad
DIN 09174356
Director01 Jan 20242 yrs 10 moSai Parenteral's Limited
Seeta Ram Anjaneyulu Gorantla
DIN 01874325
Director01 Jan 20242 yrs 10 moSai Parenteral's Limited
Kalidindi Venkateswara Raju
DIN 00788664
Director12 Nov 20241 yr 11 moSai Parenteral's Limited

People of SAI Parenterals

2 people are tracked at SAI Parenterals (2 in leadership); the tracked headcount is 257.

NameRoleGroup
Vijitha Gorrepati
Managing DirectorLeadership
Anil Kumar Karusala
Managing DirectorLeadership
Premium access

Complete people profiles for SAI Parenterals

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of SAI Parenterals

SAI Parenterals is a publicly listed company on the NSE with ticker symbol SAIPARENT in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • Listed onNSE: SAIPARENT
  • Listed entitySAI PARENTERALS LTD
  • Exchange sectorHealth technology
  • ISININE0H9F01037
  • Share price₹505.20 (+3.42% on the day) · 2026-05-07
  • Market capitalisation₹2,162 Cr
  • Volume (last session)12,465
  • Analyst consensusNo rating

Financials of SAI Parenterals

Exchange-reported figures of Sai Parenteral's Limited, the listed company behind SAI Parenterals (NSE: SAIPARENT).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹381 Cr
+133.6% YoY
EBITDA
₹38.77 Cr
-1.5% YoY
Profit After Tax
₹14.27 Cr
-1.0% YoY
Net Worth
₹491 Cr
+423.9% YoY
Total Assets
₹1,095 Cr
+475.4% YoY
Total Debt
₹469 Cr
+398.9% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Income statement
Revenue38116315496.80
Revenue growth+133.6%+6.1%+58.8%-
EBITDA38.7739.3831.6918.53
EBITDA margin+10.2%+24.1%+20.6%+19.1%
Profit before tax11.9319.9412.577.24
Net profit14.2714.428.434.36
Net profit margin+3.8%+8.8%+5.5%+4.5%
EPS (₹)3.235.436.356.12
Balance sheet
Total assets1,095190195100
Net worth49193.6774.5531.49
Total debt46993.9611968.55
Cash & bank4172.094.380.17
Net working capital49211811548.21
Cash flow
Cash from operations93.0533.15(29.76)(12.80)
Cash from investing(274)0.44(46.32)(19.03)
Cash from financing596(35.88)78.5723.98
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025
Revenue19517919896.1553.5333.39
Revenue growth (YoY)+264.1%+435.1%----
Other income3.723.742.883.131.341.17
EBITDA40.2423.5226.09(3.56)11.424.74
EBITDA margin+20.6%+13.2%+13.2%-3.7%+21.3%+14.2%
Depreciation25.098.118.185.791.441.45
Interest8.989.368.405.412.172.46
Profit before tax9.899.7912.39(11.63)9.152.00
Tax(0.62)1.86(0.76)(4.96)2.800.59
Net profit10.517.9313.15(6.67)6.351.41
EPS (₹)2.381.794.02(2.22)34.410.11
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Income statement
Revenue16612711496.80
Revenue growth+31.1%+11.1%+17.7%-
EBITDA28.4826.8621.4817.67
EBITDA margin+17.2%+21.2%+18.9%+18.3%
Profit before tax18.7714.3810.227.28
Net profit16.7810.297.204.56
Net profit margin+10.1%+8.1%+6.3%+4.7%
EPS (₹)3.803.865.416.43
Balance sheet
Total assets622163149100
Net worth48791.2278.0831.48
Total debt13371.7971.1568.55
Cash & bank4101.101.381.91
Net working capital40578.9075.7852.00
Cash flow
Cash from operations11218.68(4.43)(20.83)
Cash from investing(136)(13.16)(31.97)(17.26)
Cash from financing433(5.81)35.8830.23
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025
Revenue52.9152.7856.7938.4847.7819.20
Revenue growth (YoY)+10.7%+174.9%----
Other income3.593.410.120.750.631.24
Total expenses43.8039.4343.5734.5037.4316.17
EBITDA9.1113.3513.223.9810.353.03
EBITDA margin+17.2%+25.3%+23.3%+10.3%+21.7%+15.8%
Depreciation1.521.361.531.601.341.32
Interest2.493.573.422.121.471.76
Profit before tax8.6911.838.391.018.171.19
Tax2.212.95(1.55)0.642.530.36

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 08 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025
Revenue19517919896.1553.5333.39
Revenue growth (YoY)+264.1%+435.1%----
Other income3.723.742.883.131.341.17
EBITDA40.2423.5226.09(3.56)11.424.74
EBITDA margin+20.6%+13.2%+13.2%-3.7%+21.3%+14.2%
Depreciation25.098.118.185.791.441.45
Interest8.989.368.405.412.172.46
Profit before tax9.899.7912.39(11.63)9.152.00
Tax(0.62)1.86(0.76)(4.96)2.800.59
Net profit10.517.9313.15(6.67)6.351.41
EPS (₹)2.381.794.02(2.22)34.410.11
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Revenue38116315496.80
Revenue growth+133.6%+6.1%+58.8%-
Other income8.520.671.420.23
Total expenses34212412278.27
Employee cost29.2813.0912.648.92
EBITDA38.7739.3831.6918.53
EBITDA margin+10.2%+24.1%+20.6%+19.1%
Depreciation16.858.209.425.79
Interest18.5111.9111.125.73
Profit before tax11.9319.9412.577.24
Tax(2.34)5.494.142.88
Net profit14.2714.428.434.36
Net profit margin+3.8%+8.8%+5.5%+4.5%
EPS (₹)3.235.436.356.12
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Equity & liabilities
Share capital22.0913.3113.257.15
Reserves & surplus46980.3661.3024.34
Shareholders' funds (net worth)49193.6774.5531.49
Minority interest4.352.111.860.00
Secured loans28487.3611468.00
Unsecured loans1856.604.770.55
Total debt46993.9611968.55
Total liabilities1,095190195100
Assets
Gross block43279.5099.3355.08
Net block36453.2070.0144.47
Capital work in progress2120.500.001.60
Investments0.000.000.000.00
Inventories17251.0837.2113.19
Sundry debtors18112712761.21
Cash & bank balances4172.094.380.17
Loans & advances52.1720.1918.697.37
Total current assets82220018781.94
Total current liabilities33082.1672.7133.73
Net working capital49211811548.21
Total assets1,095190195100
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Opening cash2.094.381.909.75
Net cash from operating activities93.0533.15(29.76)(12.80)
Net cash from investing activities(274)0.44(46.32)(19.03)
Net cash from financing activities596(35.88)78.5723.98
Net change in cash415(2.30)2.48(7.85)
Closing cash4172.094.380.17
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Growth
Sales growth+133.6%+6.1%+58.8%-
EBITDA growth-1.6%+24.3%+71.0%-
PBT growth-40.2%+58.6%+73.6%+9997.0%
Net income growth-1.0%+71.1%+93.4%-
Revenue CAGR (3Y)+57.9%---
EBITDA CAGR (3Y)+27.9%---
Profitability & leverage
Net income margin+3.8%+8.9%+5.5%+4.5%
Return on capital employed+4.8%+16.7%+16.1%+13.0%
Return on net worth+4.9%+17.2%+15.9%+13.9%
Debt / equity0.961.261.772.18
Long-term debt / equity0.420.380.741.06
Interest cover84.4438.2049.9344.98
Efficiency & per share
Fixed asset turnover1.491.821.991.76
Inventory turnover3.423.696.107.34
Debtors turnover2.481.291.631.58
EPS (₹)3.235.436.356.12
Dividend per share (₹)0.000.000.000.00
Book value per share (₹)111.0835.1956.2744.03
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025
Revenue52.9152.7856.7938.4847.7819.20
Revenue growth (YoY)+10.7%+174.9%----
Other income3.593.410.120.750.631.24
Total expenses43.8039.4343.5734.5037.4316.17
EBITDA9.1113.3513.223.9810.353.03
EBITDA margin+17.2%+25.3%+23.3%+10.3%+21.7%+15.8%
Depreciation1.521.361.531.601.341.32
Interest2.493.573.422.121.471.76
Profit before tax8.6911.838.391.018.171.19
Tax2.212.95(1.55)0.642.530.36
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Revenue16612711496.80
Revenue growth+31.1%+11.1%+17.7%-
Other income4.840.321.090.21
Total expenses13799.7292.4179.13
Employee cost14.3010.9210.318.92
EBITDA28.4826.8621.4817.67
EBITDA margin+17.2%+21.2%+18.9%+18.3%
Depreciation5.785.496.185.79
Interest8.777.316.174.81
Profit before tax18.7714.3810.227.28
Tax1.994.093.042.67
Net profit16.7810.297.204.56
Net profit margin+10.1%+8.1%+6.3%+4.7%
EPS (₹)3.803.865.416.43
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Equity & liabilities
Share capital22.0913.3113.257.15
Reserves & surplus46577.9164.8324.33
Shareholders' funds (net worth)48791.2278.0831.48
Secured loans0.000.0069.3568.00
Unsecured loans13371.791.800.55
Total debt13371.7971.1568.55
Total liabilities622163149100
Assets
Gross block70.7862.1858.1755.08
Net block42.7239.9041.3844.47
Capital work in progress1.090.500.001.60
Investments15828.3928.390.00
Inventories59.5026.1918.9213.19
Sundry debtors81.2286.4984.7861.21
Cash & bank balances4101.101.381.91
Loans & advances35.9316.6615.399.42
Total current assets58713012085.73
Total current liabilities18251.5444.6933.73
Net working capital40578.9075.7852.00
Total assets622163149100
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Opening cash1.101.381.919.76
Net cash from operating activities11218.68(4.43)(20.83)
Net cash from investing activities(136)(13.16)(31.97)(17.26)
Net cash from financing activities433(5.81)35.8830.23
Net change in cash409(0.29)(0.52)(7.85)
Closing cash4101.101.381.91
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Growth
Sales growth+31.1%+11.1%+17.7%-
EBITDA growth+6.0%+25.1%+21.6%-
PBT growth+30.4%+40.8%+40.4%+9997.0%
Net income growth+63.1%+42.9%+57.9%-
Revenue CAGR (3Y)+18.8%---
EBITDA CAGR (3Y)+17.3%---
Profitability & leverage
Net income margin+10.3%+8.3%+6.3%+4.8%
Return on capital employed+7.0%+13.9%+13.1%+12.1%
Return on net worth+5.8%+12.1%+13.1%+14.6%
Debt / equity0.350.841.282.18
Long-term debt / equity0.090.180.400.81
Interest cover38.6334.1940.3340.49
Efficiency & per share
Fixed asset turnover2.442.072.011.76
Inventory turnover3.795.517.097.34
Debtors turnover1.931.451.561.58
EPS (₹)3.803.865.416.43
Dividend per share (₹)0.000.000.000.00
Book value per share (₹)110.2334.2758.9444.02

Timeline of SAI Parenterals

2 dated milestones of SAI Parenterals across 24 years, from founding to its latest funding, stage changes and deals.

  1. Founded SAI Parenterals is founded.
  2. Funding First funding round of $5.8M.

Web traffic of SAI Parenterals

The website of SAI Parenterals (saiparenterals.com) receives about 1.5K visits a month.

  • Monthly visits
    1.5K

    ▼ 37% vs previous month

Top companies in Traditional Health & Nutrition

3 companies that operate in the same segment as SAI Parenterals (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Inventia Healthcare
Oral solid drug delivery systems are manufactured and developed.
1985Mumbai, Maharashtra, IndiaUSD 42.49 MUSD 89.42 M962
Strides Pharma Science
Generic, semi-solid, and liquid dosage forms are manufactured.
1990Bengaluru, Karnataka, IndiaUSD 508.93 M4,050
Sun Pharma
Specialty generic pharmaceuticals and APIs are manufactured and marketed.
1983Mumbai, Maharashtra, IndiaUSD 6.44 B19,801
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Sai Parenterals

SAIPARENT: Q2 CONS NET PROFIT 105M RUPEES VS 63.5M (YOY); Q2 REVENUE 1.95B RUPEES VS 535M (YOY); Q2 EBITDA 403M RUPEES VS 114M (YOY); Q2 EBITDA MARGIN 20.67% VS 21.41% (YOY)
Exchange Update • 6 days ago
SAI Parenterals: Company Finalizes Purchase of 60% Interest in R&D Facility Prathyak Laboratories for ₹15 Crore.
Exchange Update • 1 month ago
Sai Parenteral's consolidated net profit rises 457.75% in the June 2026 quarter | Capital Market News - Business Standard
Business Standard • 2 months ago
Sai Parenterals arm wins ₹1,300 crore OTC medicines deal in Australia - CNBC TV18
CNBCTV18 • 4 months ago
IPO GMPs: Amir Chand Jagdish Kumar IPO vs Powerica IPO vs Sai Parenteral's IPO - what grey market hints ahead of Day 3 | Stock Market News
mint • 7 months ago
Sai Parenteral's IPO subscribed 41% on Day 2
Moneycontrol • 7 months ago
Sai Parenteral IPO: Issue details, key dates, subscription status—What investors should know
ZEE Business • 7 months ago
Sai Parenteral's IPO sees weak demand on Day 1; subscribed 0.05x, GMP hints at flat debut | Stock Market News
mint • 7 months ago
Sai Parenteral's raises over Rs 122 crore from anchor investors - The Economic Times
Economic Times • 7 months ago
Subscribe for Sai Parenterals Ltd IPO; Anand Rathi
Moneycontrol • 7 months ago
Premium access

Complete news archive for SAI Parenterals

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about SAI Parenterals

SAI Parenterals was founded in 2001 and raised its 1st funding round 24 years after it was founded.

SAI Parenterals is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.

SAI Parenterals is a funded company, having raised a total of $5.83M across 1 funding round to date. The company's 1st funding round was a Series A of $5.83M, raised on Jul 2025.

SAI Parenterals has 257 employees.

The primary company behind SAI Parenterals, Sai Parenteral's Limited, reported revenue of ₹390 Cr for FY 2026, up 134% year on year.

Sai Parenterals Limited is engaged in the research, development, and manufacturing of pharmaceutical formulations. Operations are structured across branded generic formulations and contract development manufacturing organization (CDMO) services. The portfolio covers multiple therapeutic areas such as cardiovascular, neuropsychiatry, and respiratory health. Products are manufactured in various dosage forms including injectables, tablets, and capsules. Facilities are located in Hyderabad, Telangana, with a focus on sterile injectables for critical care. Global presence is established in regulated and semi-regulated markets across Australia, Southeast Asia, and the Middle East.

SAI Parenterals offers Injectables, Branded Generic Formulations, and CDMO Services.

Yes, SAI Parenterals is publicly traded on NSE under the ticker symbol SAIPARENT.

SAI Parenterals has 3 investors. Key investors include Blue Lotus Capital, Samarsh Capital, and Vyom Partners.

SAI Parenterals operates through Sai Parenteral's Limited.

The legal entities of SAI Parenterals currently have 9 directors, including Kalidindi Venkateswara Raju, Bhagyashri Dharmasa Zad, Aruna Karusala and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available